Company / R&D Expense
MoonLake Immunotherapeutics R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$202.9M
FY2025
5-year range
$31.8M / $202.9M
FY2021-FY2025
Trend
+79.9%
vs FY2024
Sector context
#82 of 210
Health Care
What the data says
At $203M, MoonLake Immunotherapeutics's r&d expense ranks #82 of 210 in the Health Care sector. Improved from $32M to $203M over the past 2 years.
Based on SEC 10-K filings.
$203M in FY2025 with a 3-year CAGR of +69.0%.
Improved from $32M to $203M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +69.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#82 of 210 in Health CareTop 39% of 210This company $202.9M Sector average $644.1M
▼
-68.5% below sector average
Key checks
Key Insights
- 3-year CAGR of +69.0%, indicating consistent growth.
- In FY2025, r&d expense increased 79.9% year-over-year.
- Ranks #82 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $202.9M | +79.9% |
| FY2024 | $112.8M | +254.6% |
| FY2023 | $31.8M | -24.4% |
| FY2022 | $42.0M | +18.3% |
| FY2021 | $35.5M | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026